Laboratory of John Hagan, Ph.D.


The laboratory of Dr. John Hagan has two primary research interests where we seek to translate our research discoveries to the clinic to improve human health:

  1. Defining genetic factors that contribute to intracranial aneurysms using clinical genomics and animal models
  2. Understanding the role of microRNAs and their post-transcriptional regulators in development, normal physiology, and disease with an emphasis on LIN28/let-7 pathway and 3’ RNA uridylation

Dr. Hagan received his PhD from the University of Pittsburgh under Dr. Paula Grabowski. His postdoctoral training was at the National Cancer Institute with Dr. Colin Stewart, at the Ohio State University Medical Center with Dr. Carlo Croce, and lastly, at Harvard Medical School with Dr. Richard Gregory. To date, Dr. Hagan’s research has been cited more than 10,000 times.

Complete List of Published Works (from 2004, n=47, >10,000 citations, h-index=34, i10-index=39, e-index=94, Publication Metrics via Google Scholar):

About John Hagan, Ph.D.

Intracranial Aneurysm Research

An intracranial aneurysm (IA) is a weakened area in a cerebral artery wall that leads to abnormal dilatation whose rupture causes subarachnoid hemorrhage (SAH), a major cause of hemorrhagic stroke. Due to early age of onset and high mortality, SAH accounts for >25% of years lost for all stroke victims under the age of 65 years. Despite treatment advances, SAH mortality rate is 40% and only half of survivors return to independent life. There is a dire need to understand the genetic and molecular basis for IA to improve clinical outcomes through early therapeutic intervention. Genetic factors play a significant role in IA pathogenesis as illustrated by genome wide association studies (GWAS), IA-predisposing genetic syndromes, family studies, and mouse research. Of note, traditional GWAS focus on common variants (≥5% minor allele frequency) and would miss rare variants of large effect size as evidenced by IA families with autosomal dominant disease. To date, IA-predisposing syndromes and loci implicated by GWAS account for just over half the heritability of IA.

Dr. Hagan’s intracranial aneurysm research is focused on using clinical human genetics and animal models to discover novel gene mutations that contribute to intracranial aneurysm development and to define dysregulated pathways in disease that are potential therapeutic targets. Of note, recent research with multiple collaborators has identified THSD1 as a bona fide IA-causing gene whose mutation causes intracranial aneurysms in both familial and sporadic cases with supporting evidence from both zebrafish and genetically engineered mouse models.  Recently, we analyzed additional large families with at least four individuals affected by disease, identifying additional candidate genes using whole exome sequencing. Future studies are planned to use whole genome sequencing in both families and our large patient cohort to analyze the genome comprehensively to identify which candidate genes are associated with disease.

Research Accomplishments in Defining Novel Intracranial Aneurysm Disease Mutations

Since intracranial aneurysm are typically asymptomatic until their devastating rupture, it is exceptionally difficult to recruit a large patient cohort. In collaboration with the Neuroscience Research Repository, we have overcome this obstacle by a decade long quest to enroll large numbers of both patients as well as their family members with informed consent.

Hagan lab image 1

We have used cutting edge technology including whole exome sequencing to define gene mutations in families that are associated with disease with evidence of causality using animal models.  As proof-of-principle, we recently discovered how a specific mutation in the THSD1 gene contributes to the pathophysiology of intracranial aneurysms using whole exome sequencing and research in both zebrafish and mouse models. By examining a well-characterized and clearly defined cohort of patients and families affected by this type of aneurysm, we have identified the first genetic cause in a single large family, then extended this finding to other unrelated patients and families. To do so, we enrolled more than 100 affected families and clinically characterized more than 500 IA (intracranial aneurysm) probands. By performing whole exome sequencing on a large family, we were able to reveal a segregating nonsense THSD1 mutation.

Additional THSD1 mutations were then noted in 8 unrelated probands, both familial and sporadic. Thsd1 loss-of-function studies in zebrafish and mice were then used for in vivo analyses, and functional studies were performed using an in vitro endothelial cell model. We discovered Thsd1 loss-of-function in zebrafish and mice caused cerebral bleeding (which localized to the subarachnoid space in mice) and increased mortality. Mechanistically, THSD1 loss impaired endothelial cell focal adhesion to the basement membrane. These adhesion defects could be rescued by expression of wild-type THSD1 but not THSD1 mutants identified in intracranial aneurysm patients. These findings have provided new insight into intracranial aneurysm pathogenesis and new understanding of the overall function of THSD1, a protein that has been poorly characterized to date.

Hagan lab image 2 Hagan lab image 3

3’ RNA Uridylation and the LIN28/let-7 pathway

Research in the Hagan laboratory is focused on understanding the roles of 3’ RNA uridylation in regulating gene expression (both microRNAs and mRNAs) and translating these discoveries into novel cancer therapeutics. Our microRNA work revolves primarily around the LIN28/let-7 pathway that plays critical roles in cancer, glucose metabolism, tissue repair, and reprogramming (i.e., the generation of induced pluripotent stem cells).

The lab is actively pursuing understanding the role of microRNAs and their regulators in cancer with an aim of developing next generation therapeutics.  Dr. Hagan has demonstrated that the proto-oncogene LIN28 represses the tumor suppressor let-7 microRNAs. LIN28 overexpression and let-7 repression is associated with poor prognosis in a myriad of cancer types, including glioblastoma multiforme, medulloblastoma, neuroblastoma, atypical teratoid/rhabdoid tumors, multiple myeloma, liver, breast, ovarian, and colon cancers. LIN28 via a let-7 dependent mechanism is believed to promote poor cancer prognosis by promoting resistance to several frontline cancer treatments including ionizing radiation and multiple chemotherapy drugs. For LIN28A, this proto-oncogene requires the TUTase ZCCHC11 to repress let-7 biogenesis via 3’ RNA uridylation. Terminal Uridylyl Transferase (TUTase) are the enzymes responsible for 3’ RNA uridylation and are attractive targets for therapeutic intervention. Efforts are ongoing to target the LIN28/let-7 pathway to improve patient outcomes.

An additional function for the TUTases ZCCHC11 and ZCCHC6 was reported by Narry Kim’s lab. Specifically, they showed that these enzymes uridylate many polyadenylated mRNAs, resulting in their enhanced degradation. This observation is consistent with our unpublished data where we found that many tumor suppressor genes are regulated negatively by Zcchc11, independently of the Lin28/let-7 pathway. There is also evidence that TUTase inhibitors may be beneficial in other diseases and specific cancer types independent of the LIN28/Let-7 pathway.

The clinical significance of this finding is illustrated by the fact that ZCCHC11 and E2F1are a dual gene classifier that predicts poor breast cancer prognosis, independently of tumor subtype and LIN28 status. Therefore, we seek to define specific and cancer relevant changes in gene expression upon modulations of ZCCHC11 levels and understand how mechanistically some mRNA are specifically targeted by 3’ RNA uridylation.

Hagan lab image 4
Hagan lab image 5

Dr. John Hagan also leads a project to understanding the role of microRNA in meningiomas, which account for 20% of all central nervous system tumors. Previously, Dr. John Hagan in collaboration with researchers at The Hospital for Sick Children in Toronto have defined microRNA expression signatures in medulloblastoma, the most common pediatric brain cancer, that classify medulloblastoma subtypes and stratify disease outcomes.

Peer-Reviewed Publications (2004-Present)

  1. Hagan, J.P., Sewell, L., Kozlov, S.V., Chiang, Y., and Stewart, C.L.: Intraspecific Mating With CzechII/Ei Mice Rescue Lethality Associated With Loss of Function Mutations of the Imprinted Genes, Igf2r and Cdkn1c. Genomics 85: 835-843. PMID: 16778172, 2004
  2. Fan, T., Hagan, J.P., Kozlov, S.V., Stewart, C.L., and Muegge, K.: Lsh Controls Silencing of the Imprinted Cdkn1c Gene. Development 132: 635-644. PMID: 15647320, 2005
  3. Palamarchuk, A., Zanesi, N., Aqeilan, R.I., Efanov, A., Maximov, V., Santanam, U., Hagan, J.P., Croce, C.M., and Pekarsky, Y.: Tal1 transgenic expression reveals absence of B lymphocytes. Cancer Research 66: 6014-6017. PMID: 16778172, 2006
  4. Roldo, C., Missiaglia, E., N., Hagan, J.P., Falconi, M., Capelli, P., Bersani, S., Calin, G.A., Volinia, S., Liu, C.G., Scarpa, A., and Croce, C.M.: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. Journal of Clinical Oncology 24: 4677-4684. PMID: 16966691, 2006
  5. Pekarsky, Y., Santanam, U., Cimmino, A., Palamarchuk, A., Efanov, A., Maximov, V., Volinia, S., Alder, H., Liu, C.G., Rassenti, L., Calin, G.A., Kipps, T., Hagan, J.P., and Croce, C.M.: Tcl1 expression in CLL is regulated by miR-29 and miR-181. Cancer Research 66: 11590-11593. PMID: 17178851, 2006
  6. Aqeilan, R.I, Trapasso, F., Hussain, S., Costinean, S., Pekarsky, Y., Hagan, J.P., Zanesi, N., Kaou, M., Stein, G.S., Lian, J.B., and Croce, C.M.: Targeted deletion of WWOX reveals a tumor suppressor function. Proceedings National Academy of Science USA 104: 3949-3954. PMCID: PMC1820689, 2007
  7. Bloomston, M., Frankel, W.L., Petrocca, F., Volinia, S., Alder, H., Hagan, J.P., Liu, C.G., Bhatt, D., Taccioli, C., and Croce, C.M.: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Journal of the American Medical Association 297: 1901-1908. PMID: 18296647, 2007
  8. Aqeilan, R.I, Hagan, J.P., Aqeilan, H.A., Petrocca, F., Fong, L.Y., and Croce, C.M.: Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo. Cancer Research 67: 5606-5610. PMCID: PMC2621009, 2007
  9. Kebache, S., Ash, J., Annis, M.G., Hagan, J., Huber, M., Hassard, J., Stewart, C.L., Whiteway, M., and Nantel, A.: Grb10 and active Raf-1 kinase promote bad-dependent cell survival. Journal of Biological Chemistry 282: 21873-21883. PMID: 17535812, 2007
  10. Hagan, J.P.* and Croce, C.M.: MicroRNAs in Carcinogenesis. Cytogenetic and Genome Research 118: 252-259. PMID: 18000378, 2007
  11. Schmid, T., Jansen, A.P., Baker, A.R., Hegamyer, G., Hagan, J.P., and Colburn, N.H.: Tumor suppressor Pdcd4 is targeted during tumor promotion. Cancer Research 68: 1254-1260. PMID: 18296647, 2008
  12. Aqeilan, R.I., Hassan, M.Q., de Bruin, A., Hagan, J.P., Volinia, S., Palumbo, T., Hussain, S., Lee, S.H., Gaur, T., Stein, G.S., Lian, J.B., and Croce, C.M.: The WWOX tumor suppressor is essential for post-natal survival and normal bone metabolism. Journal of Biological Chemistry 283: 21629-21639. PMCID: PMC2490770, 2008
  13. Rao, Y, Lee, Y., Jarjoura, D., Ruppert, A.S., Hsu, J.C., and Hagan, J.P.: A Comparison of Normalization Techniques for MicroRNA Microarray Data. Statistical Applications in Genetics and Molecular Biology, 7: Article 22. PMID: 18673291, 2008
  14. Pichiorri, F., Suh, S.S., Ladetto, M., Kuehl, M., Palumbo,T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J.P., Munker, R., Volinia, S., Boccadoro, M., Garzon, R., Palumbo, A., Aqeilan, R.I., and Croce, C.M.: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings National Academy of Science USA 105: 12885-12890. PMCID: PMC2529070, 2008
  15. Taccioli, C., Fabbri, E., Visone, R., Volinia, S., Calin, G.A., Fong, L.Y., Gambari, R., Bottoni, A., Acunzo, M., Hagan, J., Iorio, M.V., Piovan, C., Romano, G., and Croce, C.M.: UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. Nucleic Acids Research 37: D41-48. PMCID: PMC2686429, 2009
  16. Chong, J.L., Wenzel, P.L., Saenz-Robles, M.T., Nair, V., Ferrey, A., Hagan, J.P., Gomez, Y.M., Sharma, N., Chen, H.Z., Ouseph, M., Wang, S.H., Trikha, P., Culp, B., Mezache, L., Winton, D.J., Sansom, O.J., Chen, D.N., Bremner, R., Cantalupo, P.G., Robinson, M.L., Pipas, J.M., and Leone, G.: E2f1–3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 462: 934-1025. PMCID: PMC2806193, 2009
  17. Resnick, K.E., Alder, H., Hagan, J.P., Richardson, D.L., Croce, C.M., and Cohn, D.E.: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecologic Oncology 112: 55-59. PMID: 18954897, 2009
  18. Aqeilan, R.I., Hagan, J. P., de Bruin, A., Rawahneh, M., Salah, Z., Gaudio, E., Siddiqui, H. Volinia, S., Alder, H., Lian, J.B., Stein, G.S., and Croce, C.M.: Target ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology 150: 1530-1535. PMCID: PMC2654736, 2009
  19. Hagan, J.P.*, O’Neill, B.L., Stewart, C.L., Kozlov, S.V., and Croce, C.M.: At least ten genes define the imprinted Dlk1-Dio3 cluster on mouse chromosome 12qF1. PLoS One 4: e4352. PMCID: PMC2632752, 2009
  20. Northcott, P.A.#, Fernandez-L, A.#, Hagan, J.P.#, Ellison, D.W., Grajkowska, W., Gillespie, Y., Grundy, R., Van Meter, T., Rutka, J.T., Croce, C.M., Kenney, A.M., and Taylor, M.D.: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Research 69: 3249-3255. PMCID: PMC2836891, 2009
  21. Hagan, J.P.#, Piskounova, E.#, and Gregory, R.I.: Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nature Structural & Molecular Biology 16: 1021-1025. PMCID: PMC2758923, 2009
  22. Liu, J.Q., Joshi, P.S., Wang, C., El-Omrani, H.Y., Xiao, Y., Liu, X.P., Hagan, J.P., Liu, C.G., Wu, L.C., and Bai, X.F.: Targeting activation-induced cytidine deaminase overcome tumor evasion of immunotherapy by CTLs. Journal of Immunology 184: 5435-5443. PMCID: PMC2874093, 2010
  23. Santanam, U., Zanesi, N., Efanov, A., Costinean, S., Palamarchuk, A., Hagan, J.P., Volinia, S., Alder, H., Rassenti, L., Kipps, T., Croce, C.M., and Pekarsky, Y.: Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proceedings National Academy of Science USA 107: 12210-12215. PMCID: PMC2901490, 2010
  24. Wenzel, P.L., Chong, J.L., Saenz-Robles, M.T., Ferrey, A., Hagan, J.P., Gomez, Y.M., Rajmohan, R., Sharma, N., Chen, H.Z., Pipas, J.M., Robinson, M.L., and Leone, G.: Cell proliferation in the absence of E2F1-3. Developmental Biology 351: 35-45. PMCID: PMC3868453, 2011
  25. Motiwala, T., Zanesi, N., Datta, J., Roy, S., Kutay, H., Checovich, A.M., Kaou, M., Zhong, Y., Johnson, A.J., Lucas, D.M., Heerema, N.A., Hagan, J., Mo, X., Jarjoura, D., Byrd, J.C., Croce, C.M., and Jacob. S.T.: AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood 118: 6132-6140 PMCID: PMC3234669, 2011
  26. Zhu, H., Shyh-Chang, N., Segrè, A.V., Shinoda, G., Shah, S.P., Einhorn, W.S., Takeuchi, A., Engreitz, J.M, Hagan, J.P., Kharas, M.G., Urbach, A., Thornton, J.E., Triboulet, R., Gregory, R.I., DIAGRAM Consortium, MAGIC Investigators, Altshuler, D., and Daley, G.Q.: The Lin28/let-7 axis regulates glucose metabolism. Cell 147: 81-94. PMCID: PMC3353524, 2011
  27. Piskounova, E., Polytarchou, C., Thornton, J.E., LaPierre, R.J., Pothoulakis, C., Hagan, J. P., Iliopoulos, D., and Gregory, R.I.: Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147: 1066-1079. PMCID: PMC3227872, 2011
  28. Chang, H.M., Martinez, N.J., Thornton, J.E., Hagan, J.P., Nguyen, K.D., and Gregory, R.I.: Trim71 cooperates with microRNAs to repress Cdkn1a expression and promote embryonic stem cell proliferation. Nature Communications 3: 923 PMCID: PMC3518406, 2012
  29. Abdeen, S.K., Del Mare, S., Hussain, S., Remaileh, M.A., Salah, Z., Hagan, J., Rawahneh, M., Pu, X.A., Russell, S., Stein, J.L., Stein, G.S., Lian, J.B., and Aqeilan, R.I.: Conditional inactivation of the mouse WWOX tumor suppressor gene recapitulates the null phenotype.  Journal of Cellular Physiology 228:1377-1382 PMID: 23254685, 2013
  30. Shinoda, G., de Soysa, T.Y., Seligson, M.T., Yabuuchi, A., Fujiwara, Y., Huang, P.Y., Hagan, J.P., Gregory, R.I., Moss, E.G., and Daley, G.Q.: Lin28a regulates germ cell pool size and fertility. Stem Cells 31:1001-1009 PMCID: PMC3652309, 2013
  31. Chen, L., Zhang, Y., Yang, J., Hagan, J.P., and Li, M.: Vertebrate Animal Models of Glioma: Understanding the Mechanisms and Developing New Therapies. Biochimica et Biophysica Acta-Reviews on Cancer 1836: 158-165 PMCID: PMC372903, 2013
  32. Shinoda, G., Shyh-Chang, N., de Soysa, T.Y., Zhu, H., Seligson, M.T., Shah, S.P., Abo-Sido, N., Yabuuchi, A., Hagan, J.P., Gregory, R.I., Asara, J.M., Cantley, L.C., Moss, E.G., and Daley, G.Q.: Fetal deficiency of Lin28 programs life-long aberrations in growth and glucose metabolism. Stem Cells 31:1563-1573 PMCID: PMC3775935, 2013
  33. Zhang, Y., Yang, J., Cui, X., Chen, Y., Zhu, V.F., Hagan, J.P., Wang, H., Yu, X., Hodges, S.E., Fang, J., Chiao, P.J., Logsdon, C.D., Fisher, W.E., Brunicardi, F.C., Chen, C., Yao, Q., Fernandez-Zapico, M.E., and Li. M.: A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Molecular Medicine 5:1322-1334 PMCID: PMC3799489, 2013
  34. Cui, X., Zhang, Y., Yang, J., Sun, X., Hagan, J.P., Guha, S., and Li, M.: ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Cell Cycle 13(7): 1180-1196 PMCID: PMC4013168, 2014
  35. Santiago-Sim, T., Fang, X., Hennessy, M.L., Nalbach, S.V., DePalma, S.R., Lee, M.S., Greenway, S.C., McDonough, B., Hergenroeder, G.W., Patek, K.J., Colosimo, S.M., Qualmann, K.J., Hagan, J.P., Milewicz, D.M., MacRae, C.A., Dymecki, S.M., Seidman, C.E., Seidman, J.G. and Kim, D.H.: THSD1 (Thrombospondin Type 1 Domain Containing Protein 1) Mutation in the Pathogenesis of Intracranial Aneurysm and Subarachnoid Hemorrhage. Stroke 47: 3005-3013 PMCID: PMC5134902, 2016
  36. Lee, H.J., Diaz, M.F., Price, K.M., Ozuna, J.A., Zhang, S.,Sevick-Muraca, E.M., Hagan, J.P., and Wenzel, P.L.: Fluid shear stress activates YAP1 to promote cancer cell motility. Nature Communications 8: 14122 PMCID: PMC5253685, 2017
  37. Zhen, X., Rui, Y.N., Balzeau, J., Menezes, M.R., Niu, A., Hagan, J.P., and Kim, D.H. Highly Efficient One-Step Scarless Protein Tagging by Type IIS Restriction Endonuclease-Mediated Precision Cloning. Biochemical and Biophysical Research Communications 490: 8-16 PMID: 28576485, 2017
  38. Rui, Y.N., Zhen, X., Fang, X., Menezes, M.R., Balzeau, J., Niu, A., Hagan, J.P.*, and Kim, D.H. The Intracranial Aneurysm Gene THSD1 Connects Endosome Dynamics to Nascent Focal Adhesion Assembly. Cellular Physiology and Biochemisty 43: 2200-2211 PMID: 29069646, 2017
  39. Balzeau, J., Menezes, M.R., Cao, S., and Hagan, J.P.* The LIN28/let-7 pathway in cancer. Frontiers in Genetics 8:31 PMCID: PMC5368188, 2017
  40. Zhen, X., Rui, Y.N., Hagan, J.P.*, and Kim, D.H. Precision Tagging: A Novel Seamless Protein Tagging by Combinational Use ofType II and Type IIS Restriction Endonucleases-Mediated Precision Cloning. Bio-protocol 8: e2721 PMCID: PMC5951406, 2018
  41. Kerr, K., Qualmann, K., Esquenazi, Y., Hagan, J., and Kim, D.H. Familial Syndromes Involving Meningiomas Provide Mechanistic Insight into Sporadic Disease. Neurosurgery PMID: 29660026, 2018
  42. Menezes, M.R., Balzeau, J., and Hagan, J.P.* 3’ RNA Uridylation in Epitranscriptomics, Gene Regulation, and Disease. Frontiers in Molecular Biosciences 5:61, PMCID: PMC6053540, 2018
  43. Yang, J., Zhang. Z., Zhang, Y., Ni, X., Zhang, G., Cui, X., Liu, M., Xu, C., Zhang, Q., Zhu, H., Yan, J., Zhu. V.F., Luo, Y., Hagan, J.P., Li, Z., Fang, J., Jatoi, A., Fernandez-Zapico, M.E., Zheng, L., Edil, B.H., Bronze, M.S., Houchen, C.W., Li, Y.P., and Li, M. ZIP4 Promotes Muscle Wasting and Cachexia in Mice with Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells. Gastroenterology 156(3):722-734 PMID: 30342032, 2019
  44. Sandberg, D.I., Yu, B., Patel, R., Hagan, J., Miesner, E., Sabin, J., Smith, S., Fletcher, S., Shah, M.N., and Taylor, M.D. Infusion of 5-Azacytidine (5-AZA) into the Fourth Ventricle or Resection Cavity in Children with Recurrent Posterior Fossa Ependymoma: A Pilot Clinical Trial. Journal of Neuro-Oncology 141:449-457. PMID: 30460634, 2019
  45. Zhen, X., Rui, Y.N., Hagan, J.P.*, and Kim, D.H. Intracranial Aneurysms: Pathology, Genetics, and Molecular Mechanisms. NeuroMolecular Medicine 21:325-343 PMC6829066, 2019
  46. Rui, Y.N., Chen, Y., Guo, Y., Bock, C.E., Hagan, J.P., Kim, D.H. and Zhen, X. Podosome Formation Impairs Endothelial Barrier Function by Sequestering Zonula Occludens Proteins. Journal of Cellular Physiology 235: 4655-4666 PMC7087352, 2020
  47. Yan, Y., Martinez, Rasheed, M.N., Cahal, J., Xu, Z., Rui, Y.N., Qualmann, K.J., Hagan, J.P., and Kim, D.H. Germline and somatic mutations in the pathology of pineal cyst: A whole‐exome sequencing study of 93 individuals. Molecular Genetics & Genomic Medicine e1691, PMC8222845, 2021
  48. Mohammadalipour, A., Diaz, M.F., Livingston, M., Ewere, A., Zhou, A., Horton, P.D., Olamigoke, L.T., Lamar, J.M., Hagan, J.P., Lee, H.J., and Wenzel, P.L. RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow. FASEB Bioadv. 14: 342-361, PMC9065582, 2022

# = equal contribution

* = corresponding or co-corresponding author 


  1. Kim, D.H., Santiago-Sim, T., Qualmann, K.J., O’Leary, J.S.B, Rui, Y.N., Yan, Y., Zhen, X., and Hagan, J.P., and Kim, D.H. Pathobiology of Intracranial Aneurysms. Youmans and Winn Neurological Surgery (8th edition), 2022


Provisional Patents – (All Filed on January 5, 2022 with USPTO)

  1. Inventors: Dong H. Kim, Yuanqing Yan, Yanning Rui, Zhen Xu, and John P. Hagan. Methods and Reagents for Characterizing THSD1 Function. U.S. Provisional Application No.: 63/296,817
  2. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. Autophagy as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,820
  3. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. Podosomes as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,821
  4. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. TGF-β as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,825

Patents – (All Filed on May 25, 2022 with USPTO)

  1. Inventors: Dong H. Kim, Yuanqing Yan, Yanning Rui, Zhen Xu, and John P. Hagan. Methods and Reagents for Characterizing THSD1 Function. U.S. Provisional Application No.: 63/296,817
  2. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. Autophagy as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,820
  3. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. Podosomes as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,821
  4. Inventors: Dong H. Kim, Yanning Rui, Zhen Xu, and John P. Hagan. TGF-β as a Therapeutic Target for Intracranial Aneurysm. U.S. Provisional Application No.: 63/296,825